How much did Senores' Q1 revenue grow and what drove it?

Q1 consolidated revenue rose 36% YoY to ₹180 crore, driven by a 40% jump in regulated markets, a near-doubling of approved ANDAs to 58, and the ramp-up of the Aptyp facility.

What is Senores' full-year guidance and is it credible?

Management guided for 30-40% revenue growth and 50-60% PAT growth for FY27. The Q1 PAT growth of 56% already sits at the top end of guidance, lending credibility to the target.

What is the company's plan for ANDAs and capacity?

Senores plans to commercialize 35 ANDAs over the next 18-20 months and expand oral-solid capacity. It deferred the large sterile injectable project in favor of a pilot, indicating capital discipline.

How does the Q1 performance compare to analyst expectations?

The filing does not mention analyst estimates. However, the strong Q1 beat and above-market guidance suggest the company is outpacing the broader pharma sector growth.

What are the key risks to the guidance?

Execution on ANDA launches, regulatory approvals, and the ramp-up of the Aptyp plant are key. The high P/E multiple of 50x leaves little room for error.

Earnings · Pharmaceuticals · Mid cap

Senores Pharma targets 50-60% PAT growth after Q1 beat

Revenue rose 36% to ₹180 cr, PAT up 56% to ₹31 cr. Management guided for full-year PAT growth of 50-60% and plans to commercialize 35 ANDAs over 18-20 months.

— 5 earlier stories on Senores Pharmaceuticals Ltd. →

SENORES By Tipsheet Editorial 27 Jul 2026 · 6:30 PM IST Verify on BSE · NSE

Mkt cap₹5,840 cr

P/E50.62×

ROE7.45%

Debt / eq.0.39

56% Q1 PAT growth, guiding for 50-60% for FY27

What's new

Q1 consolidated revenue up 36% YoY to ₹180 cr, PAT up 56% to ₹31 cr
Management guides for full-year revenue growth of 30-40% and PAT growth of 50-60%
Plans to commercialize 35 ANDAs over next 18-20 months; defers large sterile injectable plant

Why this matters

The guidance points to sustained momentum in regulated markets, where ANDA approvals have nearly doubled to 58. The profitability-led reset in India branded generics and the deferral of sterile injectable capex suggest capital discipline. At a P/E of 50x, delivery on the 50-60% PAT guidance is priced in.

What we're watching

Execution on the 35 ANDA launches over 18-20 months
Margins from the Aptyp plant ramp-up
Any further changes to the sterile injectable timeline

The full read

Senores Pharmaceuticals delivered a strong Q1. Revenue jumped 36% to ₹180 crore; PAT rose 56% to ₹31 crore. The regulated-markets engine, powered by a near-doubling of ANDA approvals to 58 and the Aptyp plant ramp-up, is firing. Management laid out an ambitious full-year path: 30-40% revenue growth and 50-60% PAT growth, with 35 ANDAs to commercialize over the next 18-20 months. It is also deferring a large sterile injectable project in favour of a pilot. That signals capital discipline. The stock trades at 50x trailing earnings, a multiple that demands delivery. But Q1 already lands at the top end of PAT guidance, making the target look credible rather than aspirational. Hardly a miss.

Questions answered

How much did Senores' Q1 revenue grow and what drove it?: Q1 consolidated revenue rose 36% YoY to ₹180 crore, driven by a 40% jump in regulated markets, a near-doubling of approved ANDAs to 58, and the ramp-up of the Aptyp facility.
What is Senores' full-year guidance and is it credible?: Management guided for 30-40% revenue growth and 50-60% PAT growth for FY27. The Q1 PAT growth of 56% already sits at the top end of guidance, lending credibility to the target.
What is the company's plan for ANDAs and capacity?: Senores plans to commercialize 35 ANDAs over the next 18-20 months and expand oral-solid capacity. It deferred the large sterile injectable project in favor of a pilot, indicating capital discipline.
How does the Q1 performance compare to analyst expectations?: The filing does not mention analyst estimates. However, the strong Q1 beat and above-market guidance suggest the company is outpacing the broader pharma sector growth.
What are the key risks to the guidance?: Execution on ANDA launches, regulatory approvals, and the ramp-up of the Aptyp plant are key. The high P/E multiple of 50x leaves little room for error.

Mentioned: ₹180 cr revenue · ₹31 cr PAT · 35 ANDAs

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on SENORES →

27 Jul 2026 · 6:30 PM IST Senores Pharma targets 50-60% PAT growth after Q1 beat
today Senores delays Atlanta plant, redirects ₹65 cr of IPO funds
today Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
today Senores Q1 profit rises 56% on regulated markets growth
today Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance